drugset
drugset / Trial / NCT02303184

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02303184 ↗

Phase 2 Completed 46 enrolled Clearside Biomedical, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given along with an intravitreal (IVT) injection of aflibercept compared to IVT aflibercept alone in subjects with retinal vein occlusion (RVO).

Timeline

Start
2015-01
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 4 mg Other
Background Aflibercept Protein / enzyme biologic 2 mg Intravitreal

Indications

macular retinal edema retinal vein occlusion